BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer.

AstraZeneca and Daiichi Sankyo’s Results from the primary analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to demonstrate strong and durable tumor responses in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).

Bausch + Lomb Corporation today announced that Bausch + Lomb Escrow Corp. (“Escrow Issuer”), a wholly owned subsidiary of the company, has launched an offering of $1.4 billion aggregate principal amount of new senior secured notes due 2028.

Arrowhead Pharmaceuticals Inc. today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

Cellares and Lyell Immunopharma announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership program.

Roivant announced that it completed the redemption of its outstanding public warrants and private placement warrants that remained outstanding following 5:00 p.m. New York City Time on September 1, 2023 for a redemption price of $0.10 per Warrant.

Crinetics Pharmaceuticals, Inc. announced that on September 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 191,107 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

ENA Respiratory announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of complications associated with respiratory viral infections.

Moderna, Inc. (NASDAQ: MRNA, “Moderna”) and Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the first participant has been dosed in the CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life extended monoclonal antibody, for the prevention of symptomatic COVID-19.